关于布鲁顿酪氨酸激酶抑制剂安全性临床管理的循证专家共识(2024 年)。

IF 7 2区 医学 Q1 ONCOLOGY Chinese Journal of Cancer Research Pub Date : 2024-06-30 DOI:10.21147/j.issn.1000-9604.2024.03.02
Zaiwei Song, Dan Jiang, Lingling Yu, Yixuan Chen, Daobin Zhou, Yue Li, Depei Wu, Lingli Zhang, Liyan Miao, Jun Ma, Jun Zhu, Hongmei Jing, Rongsheng Zhao, On Behalf Of The Steering Committee, The Consensus Panel And The Evidence Synthesis Group Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa, Hospital Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa, Division Of Therapeutic Drug Monitoring Of Chinese Pharmacological Society Cps, Expert Committee On Lymphoma Of Chinese Society Of Clinical Oncology Csco, Expert Committee On Leukemia Of Chinese Society Of Clinical Oncology Csco, Society Of Integrative Cardio-Oncology Of China Anti-Cancer Association Caca, Chinese Society Of Hematology Of Chinese Medical Association Cma, Hospital Pharmacy Professional Committee Of Cross-Straits Medicine Exchange Association Smea
{"title":"关于布鲁顿酪氨酸激酶抑制剂安全性临床管理的循证专家共识(2024 年)。","authors":"Zaiwei Song, Dan Jiang, Lingling Yu, Yixuan Chen, Daobin Zhou, Yue Li, Depei Wu, Lingli Zhang, Liyan Miao, Jun Ma, Jun Zhu, Hongmei Jing, Rongsheng Zhao, On Behalf Of The Steering Committee, The Consensus Panel And The Evidence Synthesis Group Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa, Hospital Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa, Division Of Therapeutic Drug Monitoring Of Chinese Pharmacological Society Cps, Expert Committee On Lymphoma Of Chinese Society Of Clinical Oncology Csco, Expert Committee On Leukemia Of Chinese Society Of Clinical Oncology Csco, Society Of Integrative Cardio-Oncology Of China Anti-Cancer Association Caca, Chinese Society Of Hematology Of Chinese Medical Association Cma, Hospital Pharmacy Professional Committee Of Cross-Straits Medicine Exchange Association Smea","doi":"10.21147/j.issn.1000-9604.2024.03.02","DOIUrl":null,"url":null,"abstract":"<p><p>Bruton's tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy. A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment. A multidisciplinary consensus working group was established, comprising 35 members from the fields of hematology, cardiovascular disease, cardio-oncology, clinical pharmacy, and evidence-based medicine. This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method. The Joanna Briggs Institute Critical Appraisal (JBI) tool and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach were used to rate the quality of evidence and grade the strength of recommendations, respectively. This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains, including the management of common adverse drug events such as bleeding, cardiovascular events, and hematological toxicity, as well as the management of drug-drug interactions and guidance for special populations. This multidisciplinary expert consensus could contribute to promoting a multi-dimensional, comprehensive and standardized management of BTKis.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"36 3","pages":"240-256"},"PeriodicalIF":7.0000,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230885/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).\",\"authors\":\"Zaiwei Song, Dan Jiang, Lingling Yu, Yixuan Chen, Daobin Zhou, Yue Li, Depei Wu, Lingli Zhang, Liyan Miao, Jun Ma, Jun Zhu, Hongmei Jing, Rongsheng Zhao, On Behalf Of The Steering Committee, The Consensus Panel And The Evidence Synthesis Group Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa, Hospital Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa, Division Of Therapeutic Drug Monitoring Of Chinese Pharmacological Society Cps, Expert Committee On Lymphoma Of Chinese Society Of Clinical Oncology Csco, Expert Committee On Leukemia Of Chinese Society Of Clinical Oncology Csco, Society Of Integrative Cardio-Oncology Of China Anti-Cancer Association Caca, Chinese Society Of Hematology Of Chinese Medical Association Cma, Hospital Pharmacy Professional Committee Of Cross-Straits Medicine Exchange Association Smea\",\"doi\":\"10.21147/j.issn.1000-9604.2024.03.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bruton's tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy. A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment. A multidisciplinary consensus working group was established, comprising 35 members from the fields of hematology, cardiovascular disease, cardio-oncology, clinical pharmacy, and evidence-based medicine. This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method. The Joanna Briggs Institute Critical Appraisal (JBI) tool and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach were used to rate the quality of evidence and grade the strength of recommendations, respectively. This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains, including the management of common adverse drug events such as bleeding, cardiovascular events, and hematological toxicity, as well as the management of drug-drug interactions and guidance for special populations. This multidisciplinary expert consensus could contribute to promoting a multi-dimensional, comprehensive and standardized management of BTKis.</p>\",\"PeriodicalId\":9882,\"journal\":{\"name\":\"Chinese Journal of Cancer Research\",\"volume\":\"36 3\",\"pages\":\"240-256\"},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2024-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230885/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21147/j.issn.1000-9604.2024.03.02\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2024.03.02","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

布鲁顿酪氨酸激酶抑制剂(BTKis)彻底改变了B细胞淋巴瘤的治疗方法。然而,与使用 BTKis 相关的安全性问题可能会阻碍治疗的持续性,并进一步影响临床疗效。目前还缺乏从药理学角度对与 BTKi 治疗相关的安全性问题达成全面、系统的专家共识。我们成立了一个多学科共识工作组,由来自血液学、心血管疾病、心肿瘤学、临床药学和循证医学领域的 35 名成员组成。该循证专家共识是采用循证方法和德尔菲法达成的。乔安娜-布里格斯研究所(Joanna Briggs Institute)的批判性评估(JBI)工具和建议评估、发展和评价分级(GRADE)方法分别用于评价证据的质量和建议的强度。该共识从三个领域的九个方面为 BTKis 药物治疗提供了实用建议,包括出血、心血管事件和血液毒性等常见药物不良事件的处理,以及药物间相互作用的处理和特殊人群的指导。这一多学科专家共识有助于促进对 BTKis 的多维、全面和标准化管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).

Bruton's tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy. A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment. A multidisciplinary consensus working group was established, comprising 35 members from the fields of hematology, cardiovascular disease, cardio-oncology, clinical pharmacy, and evidence-based medicine. This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method. The Joanna Briggs Institute Critical Appraisal (JBI) tool and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach were used to rate the quality of evidence and grade the strength of recommendations, respectively. This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains, including the management of common adverse drug events such as bleeding, cardiovascular events, and hematological toxicity, as well as the management of drug-drug interactions and guidance for special populations. This multidisciplinary expert consensus could contribute to promoting a multi-dimensional, comprehensive and standardized management of BTKis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
9.80%
发文量
1726
审稿时长
4.5 months
期刊介绍: Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.
期刊最新文献
Artificial intelligence efficiently predicts gastric lesions, Helicobacter pylori infection and lymph node metastasis upon endoscopic images. Deep learning-based automatic pipeline system for predicting lateral cervical lymph node metastasis in patients with papillary thyroid carcinoma using computed tomography: A multi-center study. Effect of visceral obesity on outcomes of fluorescence-guided lymphadenectomy during laparoscopic gastrectomy for gastric cancer: Post hoc analysis of a randomized phase 3 trial. Epidemiology of biliary tract cancer in China: A narrative review. Non-small cell lung cancer organoids: Advances and challenges in current applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1